Cleveland Clinic has teamed with AcelRx Pharmaceuticals to study the effects of DSUVIA, a synthetic opioid tablet, on patients recovering from orthopedic surgery.
A recent DSUVIA study noted a significant decrease in the amount of opioids used in the post-anesthesia care unit, according to Pamela Palmer, MD, PhD, co-founder and CMO of AcelRx Pharmaceuticals.
Study results also found a substantial decrease in the time to discharge from the post-anesthesia care unit for patients treated with DSUVIA, compared to historical controls.
AcelRx Pharmaceuticals continues to explore the efficacy of DSUVIA in intra- and postoperative care, and aims to engage in further studies examining its use outside of post-surgical care.
*Note: This article was updated to clarify that study results showed a substantial decrease in the time to discharge form the PACU for patients treated with DSUVIA. The original article reported a "substantial increase" in that time and was corrected at 12:25 pm CST on Aug. 27.